Biofrontera Competitors and Similar CompaniesClear all

Biofrontera's competitors and similar companies include Skyepharma, Affimed N.V., Avid Bioservices and Zogenix.

	Biofrontera Biofrontera is a biopharmaceutical company that specializes in the development and commercialization of dermatological medications and medical cosmetics.	Skyepharma Skyepharma is a drug delivery company developing oral and inhalation products.	Affimed N.V. Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies.	Avid Bioservices Avid Bioservices, formerly Peregrine Pharmaceuticals, is a biopharmaceutical company.	Zogenix Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology.
Founding Date	Founding Date 2012	Founding Date 1996	Founding Date 2000	Founding Date 1981	Founding Date 2006
Type	Type Public	Type Subsidiary	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare clinics pharma	Tags Healthcare clinics pharma	Tags Healthcare clinics pharma	Tags Healthcare clinics pharma	Tags Healthcare clinics pharma
Locations	Locations Leverkusen, DE HQ	Locations Saint-Quentin-Fallavier, FR HQ	Locations Heidelberg, DE HQ	Locations Tustin, US HQ	Locations Emeryville, US HQ Maidenhead, GB
Employees	Employees 91	Employees 2453% increase	Employees 76	Employees 21114% increase	Employees 743% increase
Valuation ($)	Valuation ($) 1.1 m	Valuation ($) N/A	Valuation ($) 52.5 m	Valuation ($) 649.4 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) €13.2m (FY, 2025)	Revenue (est.) £95.9m (FY, 2015)	Revenue (est.) €8.3m (FY, 2023)	Revenue (est.) $139.9m (FY, 2024)	Revenue (est.) $81.7m (FY, 2021)
Cost of goods	Cost of goods €2.2m (FY, 2025)	Cost of goods £43.1m (FY, 2015)	Cost of goods N/A	Cost of goods $132.6m (FY, 2024)	Cost of goods $4.8m (FY, 2021)
Gross profit	Gross profit €11.2m (FY, 2025)	Gross profit £52.8m (FY, 2015)	Gross profit €13m (FY, 2023)	Gross profit $7.3m (FY, 2024)	Gross profit N/A
Net income	Net income (€6.9m) (FY, 2025)	Net income N/A	Net income (€105.9m) (FY, 2023)	Net income ($140.8m) (FY, 2024)	Net income ($227.4m) (FY, 2021)